These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Thymic malignancies: next-generation sequencing as a tool to select patients for targeted therapies and immunotherapies? Girard N Mediastinum; 2019; 3():38. PubMed ID: 35118264 [TBL] [Abstract][Full Text] [Related]
3. Novel Agents in the Treatment of Thymic Malignancies. Merveilleux du Vignaux C; Maury JM; Girard N Curr Treat Options Oncol; 2017 Aug; 18(9):52. PubMed ID: 28795288 [TBL] [Abstract][Full Text] [Related]
4. Do thymic malignancies respond to target therapies? Hu B; Rong H; Han Y; Li Q Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):855-9. PubMed ID: 25754373 [TBL] [Abstract][Full Text] [Related]
6. Systemic therapeutic options in thymic malignancies: a glimmer of hope. Hammond-Thelin LA; Thomas CR Rev Recent Clin Trials; 2007 Sep; 2(3):191-205. PubMed ID: 18474005 [TBL] [Abstract][Full Text] [Related]
7. Systemic treatment for thymic malignancies. Girard N; Merveilleux du Vignaux C Curr Opin Oncol; 2017 Mar; 29(2):112-117. PubMed ID: 28027106 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and targeted agents for thymic malignancies. Girard N Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902 [TBL] [Abstract][Full Text] [Related]
9. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic options in thymomas and thymic carcinomas. Muto Y; Okuma Y Expert Rev Anticancer Ther; 2022 Apr; 22(4):401-413. PubMed ID: 35266421 [TBL] [Abstract][Full Text] [Related]
11. The role of chemotherapy in advanced thymoma. Schmitt J; Loehrer PJ J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S357-60. PubMed ID: 20859133 [TBL] [Abstract][Full Text] [Related]
12. Systemic treatment of advanced thymic malignancies. Kelly RJ Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125 [TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for advanced thymic tumors. Rajan A; Giaccone G J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S361-4. PubMed ID: 20859134 [TBL] [Abstract][Full Text] [Related]
14. Thymic malignancies: Moving forward with new systemic treatments. Remon J; Lindsay CR; Bluthgen MV; Besse B Cancer Treat Rev; 2016 May; 46():27-34. PubMed ID: 27057658 [TBL] [Abstract][Full Text] [Related]
15. Thymic tumors: relevant molecular data in the clinic. Girard N J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122 [TBL] [Abstract][Full Text] [Related]
16. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy. Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757 [TBL] [Abstract][Full Text] [Related]
17. Sunitinib effective for rare thymus cancer. Cancer Discov; 2015 Apr; 5(4):340. PubMed ID: 25680712 [TBL] [Abstract][Full Text] [Related]
18. Thymic malignancies: from clinical management to targeted therapies. Kelly RJ; Petrini I; Rajan A; Wang Y; Giaccone G J Clin Oncol; 2011 Dec; 29(36):4820-7. PubMed ID: 22105817 [TBL] [Abstract][Full Text] [Related]
19. Thymic neoplasms: an update on the use of chemotherapy and new targeted therapies. A literature review. Berardi R; De Lisa M; Pagliaretta S; Onofri A; Morgese F; Savini A; Ballatore Z; Caramanti M; Santoni M; Mazzanti P; Cascinu S Cancer Treat Rev; 2014 May; 40(4):495-506. PubMed ID: 24355362 [TBL] [Abstract][Full Text] [Related]
20. Current Drug Targets for Thymic Neoplasms. Xu XL; Mao WM Curr Cancer Drug Targets; 2015; 15(7):593-603. PubMed ID: 26077729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]